BioCentury | Dec 13, 2017
Distillery Techniques

Assay and screens

...therapy in all patients, based on a low or high MARs, respectively. Next steps by Travera LLC...
...rates (MARs) to predict patient responses in multiple myeloma (MM) LICENSING STATUS: Patented; licensed to Travera LLC...
...R. Manalis, Massachusetts Institute of Technology, Cambridge, Mass. email: srm@mit.edu Jennie Walters Revlimid Velcade Massachusetts Institute of Technology Travera LLC Multiple myeloma (MM) Travera...
Items per page:
1 - 1 of 1
BioCentury | Dec 13, 2017
Distillery Techniques

Assay and screens

...therapy in all patients, based on a low or high MARs, respectively. Next steps by Travera LLC...
...rates (MARs) to predict patient responses in multiple myeloma (MM) LICENSING STATUS: Patented; licensed to Travera LLC...
...R. Manalis, Massachusetts Institute of Technology, Cambridge, Mass. email: srm@mit.edu Jennie Walters Revlimid Velcade Massachusetts Institute of Technology Travera LLC Multiple myeloma (MM) Travera...
Items per page:
1 - 1 of 1